A Myriad of Pathways to NASH

被引:33
作者
Larrain, Soledad [1 ]
Rinella, Mary E. [1 ]
机构
[1] Northwestern Univ, Div Gastroenterol & Hepatol, Dept Med, Feinberg Sch Med, Chicago, IL 60611 USA
关键词
Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; NASH; Drug; Nutrition; Endocrine; Metabolism; NONALCOHOLIC FATTY LIVER; INTESTINAL BACTERIAL OVERGROWTH; MITOCHONDRIAL BETA-OXIDATION; INFLAMMATORY-BOWEL-DISEASE; HEPATIC CB1 RECEPTORS; CHAIN ACYL-COENZYME; PLASMA-FREE CHOLINE; GROWTH-HORMONE; PARENTERAL-NUTRITION; INSULIN-RESISTANCE;
D O I
10.1016/j.cld.2012.05.009
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Nonalcoholic steatohepatitis (NASH) is defined histopathologically by the presence of macrovesicular steatosis, cellular ballooning, and inflammation. NASH represents a complex multifactorial disease that typically occurs within the context of the metabolic syndrome. NASH lacks homogeneity, and other forms of NASH can present atypically. Less than 50% of patients with NASH respond to pharmacologic treatment, which speaks to this heterogeneity. The authors discuss drugs, disease entities, and nutritional states that can cause or exacerbate underlying NASH indirectly through worsening insulin resistance or directly by interfering with lipid metabolism, promoting oxidative injury, or activating inflammatory pathways.
引用
收藏
页码:525 / +
页数:26
相关论文
共 50 条
[21]   PREVALENCE OF NASH AMONG DIABETES [J].
Krishnamurthy, Sheela .
JOURNAL OF EVOLUTION OF MEDICAL AND DENTAL SCIENCES-JEMDS, 2019, 8 (07) :451-453
[22]   Pathophysiology of NASH in endocrine diseases [J].
Gariani, Karim ;
Jornayvaz, Francois R. .
ENDOCRINE CONNECTIONS, 2021, 10 (02) :R52-R65
[23]   Pharmacotherapy for NASH: Current and emerging [J].
Konerman, Monica A. ;
Jones, Jacob C. ;
Harrison, Stephen A. .
JOURNAL OF HEPATOLOGY, 2018, 68 (02) :362-375
[24]   Noninvasive Diagnosis of NAFLD and NASH [J].
Piazzolla, Valeria Annarita ;
Mangia, Alessandra .
CELLS, 2020, 9 (04)
[25]   NASH in Nondiabetic Endocrine Disorders [J].
Wang, Timothy ;
Yang, Wei ;
Karakas, Sidika ;
Sarkar, Souvik .
METABOLIC SYNDROME AND RELATED DISORDERS, 2018, 16 (07) :315-320
[26]   Salidroside in the Treatment of NAFLD/NASH [J].
Qu, Baozhen ;
Liu, Xuemao ;
Liang, Yanjiao ;
Zheng, Keke ;
Zhang, Chunling ;
Lu, Linlin .
CHEMISTRY & BIODIVERSITY, 2022, 19 (12)
[27]   Comprehensive Transcriptome Profiling of NAFLD- and NASH-Induced Skeletal Muscle Dysfunction [J].
Guo, Mingwei ;
Xiang, Liping ;
Yao, Jing ;
Zhang, Jun ;
Zhu, Shuangshuang ;
Wang, Dongmei ;
Liu, Caizhi ;
Li, Guoqiang ;
Wang, Jiawen ;
Gao, Yuqing ;
Xie, Cen ;
Ma, Xinran ;
Xu, Lingyan ;
Zhou, Jian .
FRONTIERS IN ENDOCRINOLOGY, 2022, 13
[28]   Histological findings and NAFLD/NASH Status in liver biopsies of patients subjected to bariatric surgery [J].
Malucelli, Marielle ;
Strobel, Rodrigo ;
Ivantes, Claudia ;
Sakamoto, Danielle ;
Duarte, Marcio Luis ;
Pedroso, Maria Lucia Alves .
ARCHIVES OF ENDOCRINOLOGY METABOLISM, 2024, 68 (01)
[29]   Pathogenesis of NASH and Promising Natural Products [J].
Leng Ying-Rong ;
Zhang Mei-Hui ;
Luo Jian-Guang ;
Zhang Hao .
CHINESE JOURNAL OF NATURAL MEDICINES, 2021, 19 (01) :12-27
[30]   Steatosis and NASH in type 2 diabetes [J].
Hu, Mengyue ;
Phan, Franck ;
Bourron, Olivier ;
Ferre, Pascal ;
Foufelle, Fabienne .
BIOCHIMIE, 2017, 143 :37-41